Thousands of Australian cancer patients are accessing genome-directed therapies via a national precision oncology program, with many seeing positive results, Garvan Institute of Medical Research Kinghorn Cancer Centre Director Professor David Thomas told the COSA 2021 Annual Scientific Meeting. The Molecular Screening and Therapeutics (MoST) study, run through Professor Thomas’ company Omico, aims to improve ...
MoST study shows promise of precision medicine – Professor David Thomas
By Natasha Doyle
29 Nov 2021